Biotech Values

[ciotera]

Re: Imbruvica

Although your (and Abbvie's) description is technically correct, it is important to provide more context to the study - it was in elderly patients, was tested against chlorambucil (which has very limited efficacy and is used in this population because elderly patients cannot tolerate the real SOC which is FCR), and the toughest to treat group (17p del) were excluded.

To say that Imbruvica beat first-line chemo in CLL implies that it beat FCR or BR which is not the case. Chlorambucil is used for its tolerability not efficacy (nobody who can get FCR or BR will be getting chlorambucil, it's almost a "palliative" treatment).